Mapping Complex Traits in a Diversity Outbred F1 Mouse Population Identifies Germline Modifiers of Metastasis in Human Prostate Cancer

Cell Systems

Volumn 4, Issue 1, 2017, Pages 31-45.e6

  Winter, Jean M ^a   Gildea, Derek E ^a   Andreas, Jonathan P ^a   Gatti, Daniel M ^b   Williams, Kendra A ^a   Lee, Minnkyong ^a   Hu, Ying ^c   Zhang, Suiyuan ^a   Mullikin, James C ^a   Wolfsberg, Tyra G ^a   McDonnell, Shannon K ^d   Fogarty, Zachary C ^d   Larson, Melissa C ^d   French, Amy J ^d   Schaid, Daniel J ^d   Thibodeau, Stephen N ^d   Churchill, Gary A ^b   Crawford, Nigel P S ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b JACKSON LABORATORY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d Mayo Clinic   (United States)

Author keywords

CASP3; CENPU; diversity outbred; DO; germline modifiers; metastasis; modifier locus mapping; neuroendocrine prostate cancer; RWDD4; systems genetics; TRAMP mouse model

Indexed keywords

CENPU PROTEIN; PROTEIN; RWDD4 PROTEIN; UNCLASSIFIED DRUG; CASP3 PROTEIN, MOUSE; CASPASE 3; CELL CYCLE PROTEIN; MLF1-IP PROTEIN, MOUSE;

AGGRESSIVENESS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PATIENT; CARCINOGENESIS; CELL CYCLE REGULATION; CENTROMERE; CHROMOSOME 8; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS FREE SURVIVAL; DNA DAMAGE CHECKPOINT; DNA DAMAGE RESPONSE; DNA RECOMBINATION; DNA REPAIR; DNA REPLICATION; GENE IDENTIFICATION; GENE MAPPING; GENE OVEREXPRESSION; GENETIC BACKGROUND; GENETIC VARIABILITY; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; GLEASON SCORE; HAPLOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROSTATE TISSUE; QUANTITATIVE TRAIT LOCUS; REAL TIME POLYMERASE CHAIN REACTION; RNA SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION INITIATION SITE; TRANSCRIPTOMICS; UPREGULATION; ANIMAL; CHROMOSOMAL MAPPING; DISEASE MODEL; GENETICS; GERM CELL; GERMLINE MUTATION; METABOLISM; MULTIFACTORIAL INHERITANCE; ONCOGENESIS AND MALIGNANT TRANSFORMATION; PATHOLOGY; PHENOTYPE; PHYSIOLOGY; POPULATION GENETICS; PROCEDURES; PROSTATE TUMOR;

ANIMALS; CASPASE 3; CELL CYCLE PROTEINS; CHROMOSOME MAPPING; COLLABORATIVE CROSS MICE; DISEASE MODELS, ANIMAL; GENETICS, POPULATION; GENOME-WIDE ASSOCIATION STUDY; GERM CELLS; GERM-LINE MUTATION; HUMANS; MALE; MICE; MULTIFACTORIAL INHERITANCE; NEOPLASM METASTASIS; NEOPLASTIC PROCESSES; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; QUANTITATIVE TRAIT LOCI;

EID: 85007506884     PISSN: 24054712     EISSN: 24054720     Source Type: Journal    
DOI: 10.1016/j.cels.2016.10.018     Document Type: Article

References (57)

1. Aizer, A.A., Gu, X., Chen, M.H., Choueiri, T.K., Martin, N.E., Efstathiou, J.A., Hyatt, A.S., Graham, P.L., Trinh, Q.D., Hu, J.C., Nguyen, P.L., Cost implications and complications of overtreatment of low-risk prostate cancer in the United States. J. Natl. Compr. Canc. Netw. 13 (2015), 61–68.
2. Alsarraj, J., Walker, R.C., Webster, J.D., Geiger, T.R., Crawford, N.P., Simpson, R.M., Ozato, K., Hunter, K.W., Deletion of the proline-rich region of the murine metastasis susceptibility gene Brd4 promotes epithelial-to-mesenchymal transition- and stem cell-like conversion. Cancer Res. 71 (2011), 3121–3131.
3. Aytes, A., Mitrofanova, A., Lefebvre, C., Alvarez, M.J., Castillo-Martin, M., Zheng, T., Eastham, J.A., Gopalan, A., Pienta, K.J., Shen, M.M., et al. Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. Cancer Cell 25 (2014), 638–651.
4. Barrett, J.C., Fry, B., Maller, J., Daly, M.J., Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21 (2005), 263–265.
5. Beltran, H., Tagawa, S.T., Park, K., MacDonald, T., Milowsky, M.I., Mosquera, J.M., Rubin, M.A., Nanus, D.M., Challenges in recognizing treatment-related neuroendocrine prostate cancer. J. Clin. Oncol. 30 (2012), e386–e389.
6. Benjamini, Y., Drai, D., Elmer, G., Kafkafi, N., Golani, I., Controlling the false discovery rate in behavior genetics research. Behav. Brain Res. 125 (2001), 279–284.
7. Björkegren, J.L., Kovacic, J.C., Dudley, J.T., Schadt, E.E., Genome-wide significant loci: how important are they? Systems genetics to understand heritability of coronary artery disease and other common complex disorders. J. Am. Coll. Cardiol. 65 (2015), 830–845.
8. Bolger, A.M., Lohse, M., Usadel, B., Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30 (2014), 2114–2120.
9. Browning, B.L., Browning, S.R., A unified approach to genotype imputation and haplotype-phase inference for large data sets of trios and unrelated individuals. Am. J. Hum. Genet. 84 (2009), 210–223.
10. Campbell, J.P., Merkel, A.R., Masood-Campbell, S.K., Elefteriou, F., Sterling, J.A., Models of bone metastasis. J. Vis. Exp., 67, 2012, e4260.
11. Cerami, E., Gao, J., Dogrusoz, U., Gross, B.E., Sumer, S.O., Aksoy, B.A., Jacobsen, A., Byrne, C.J., Heuer, M.L., Larsson, E., et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2 (2012), 401–404.
12. Chang, C.C., Chow, C.C., Tellier, L.C., Vattikuti, S., Purcell, S.M., Lee, J.J., Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience, 4, 2015, 7.
13. Chiaverotti, T., Couto, S.S., Donjacour, A., Mao, J.H., Nagase, H., Cardiff, R.D., Cunha, G.R., Balmain, A., Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am. J. Pathol. 172 (2008), 236–246.
14. Christensen, G.B., Camp, N.J., Farnham, J.M., Cannon-Albright, L.A., Genome-wide linkage analysis for aggressive prostate cancer in Utah high-risk pedigrees. Prostate 67 (2007), 605–613.
15. Church, R.J., Gatti, D.M., Urban, T.J., Long, N., Yang, X., Shi, Q., Eaddy, J.S., Mosedale, M., Ballard, S., Churchill, G.A., et al. Sensitivity to hepatotoxicity due to epigallocatechin gallate is affected by genetic background in diversity outbred mice. Food Chem. Toxicol. 76 (2015), 19–26.
16. Churchill, G.A., Doerge, R.W., Empirical threshold values for quantitative trait mapping. Genetics 138 (1994), 963–971.
17. Churchill, G.A., Gatti, D.M., Munger, S.C., Svenson, K.L., The Diversity Outbred mouse population. Mamm. Genome 23 (2012), 713–718.
18. Delaneau, O., Zagury, J.F., Marchini, J., Improved whole-chromosome phasing for disease and population genetic studies. Nat. Methods 10 (2013), 5–6.
19. Drinkwater, N.R., Gould, M.N., The long path from QTL to gene. PLoS Genet., 8, 2012, e1002975.
20. Erho, N., Crisan, A., Vergara, I.A., Mitra, A.P., Ghadessi, M., Buerki, C., Bergstralh, E.J., Kollmeyer, T., Fink, S., Haddad, Z., et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS ONE, 8, 2013, e66855.
21. Farber, C.R., Systems-level analysis of genome-wide association data. G3 (Bethesda) 3 (2013), 119–129.
22. French, J.E., Gatti, D.M., Morgan, D.L., Kissling, G.E., Shockley, K.R., Knudsen, G.A., Shepard, K.G., Price, H.C., King, D., Witt, K.L., et al. Diversity Outbred mice identify population-based exposure thresholds and genetic factors that influence benzene-induced genotoxicity. Environ. Health Perspect. 123 (2015), 237–245.
23. Gao, J., Aksoy, B.A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S.O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal., 6, 2013, pl1.
24. Gatti, D.M., Svenson, K.L., Shabalin, A., Wu, L.Y., Valdar, W., Simecek, P., Goodwin, N., Cheng, R., Pomp, D., Palmer, A., et al. Quantitative trait locus mapping methods for diversity outbred mice. G3 (Bethesda) 4 (2014), 1623–1633.
25. Gingrich, J.R., Barrios, R.J., Kattan, M.W., Nahm, H.S., Finegold, M.J., Greenberg, N.M., Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res. 57 (1997), 4687–4691.
26. Gohagan, J.K., Prorok, P.C., Hayes, R.B., Kramer, B.S., Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control. Clin. Trials 21:6, Suppl (2000), 251S–272S.
27. Hayes, J.H., Barry, M.J., Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. JAMA 311 (2014), 1143–1149.
28. Hemminki, K., Ji, J., Försti, A., Sundquist, J., Lenner, P., Concordance of survival in family members with prostate cancer. J. Clin. Oncol. 26 (2008), 1705–1709.
29. Howie, B., Fuchsberger, C., Stephens, M., Marchini, J., Abecasis, G.R., Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat. Genet. 44 (2012), 955–959.
30. Hurwitz, A.A., Foster, B.A., Allison, J.P., Greenberg, N.M., Kwon, E.D., The TRAMP mouse as a model for prostate cancer. Curr. Protoc. Immunol., Chapter 20, 2001, Unit 20.5.
31. Jin, G., Lu, L., Cooney, K.A., Ray, A.M., Zuhlke, K.A., Lange, E.M., Cannon-Albright, L.A., Camp, N.J., Teerlink, C.C., Fitzgerald, L.M., et al., International Consortium for Prostate Cancer Genetics. Validation of prostate cancer risk-related loci identified from genome-wide association studies using family-based association analysis: evidence from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum. Genet. 131 (2012), 1095–1103.
32. Kalari, K.R., Nair, A.A., Bhavsar, J.D., O'Brien, D.R., Davila, J.I., Bockol, M.A., Nie, J., Tang, X., Baheti, S., Doughty, J.B., et al. MAP-RSeq: Mayo Analysis Pipeline for RNA sequencing. BMC Bioinformatics, 15, 2014, 224.
33. Lee, M., Dworkin, A.M., Gildea, D., Trivedi, N.S., Moorhead, G.B., Crawford, N.P., NISC Comparative Sequencing Program. RRP1B is a metastasis modifier that regulates the expression of alternative mRNA isoforms through interactions with SRSF1. Oncogene 33 (2014), 1818–1827.
34. Lee, M., Dworkin, A.M., Lichtenberg, J., Patel, S.J., Trivedi, N.S., Gildea, D., Bodine, D.M., Crawford, N.P., Metastasis-associated protein ribosomal RNA processing 1 homolog B (RRP1B) modulates metastasis through regulation of histone methylation. Mol. Cancer Res. 12 (2014), 1818–1828.
35. Lee, M., Williams, K.A., Hu, Y., Andreas, J., Patel, S.J., Zhang, S., Crawford, N.P., GNL3 and SKA3 are novel prostate cancer metastasis susceptibility genes. Clin. Exp. Metastasis 32 (2015), 769–782.
36. Li, B., Dewey, C.N., RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics, 12, 2011, 323.
37. Morgan, A.P., Fu, C.P., Kao, C.Y., Welsh, C.E., Didion, J.P., Yadgary, L., Hyacinth, L., Ferris, M.T., Bell, T.A., Miller, D.R., et al. The Mouse Universal genotyping array: from substrains to subspecies. G3 (Bethesda) 6 (2015), 263–279.
38. Munger, S.C., Raghupathy, N., Choi, K., Simons, A.K., Gatti, D.M., Hinerfeld, D.A., Svenson, K.L., Keller, M.P., Attie, A.D., Hibbs, M.A., et al. RNA-Seq alignment to individualized genomes improves transcript abundance estimates in multiparent populations. Genetics 198 (2014), 59–73.
39. Ostrander, E.A., Kwon, E.M., Stanford, J.L., Genetic susceptibility to aggressive prostate cancer. Cancer Epidemiol. Biomarkers Prev. 15 (2006), 1761–1764.
40. Patel, S.J., Molinolo, A.A., Gutkind, S., Crawford, N.P., Germline genetic variation modulates tumor progression and metastasis in a mouse model of neuroendocrine prostate carcinoma. PLoS ONE, 8, 2013, e61848.
41. Prorok, P.C., Andriole, G.L., Bresalier, R.S., Buys, S.S., Chia, D., Crawford, E.D., Fogel, R., Gelmann, E.P., Gilbert, F., Hasson, M.A., et al., Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control. Clin. Trials 21:6, Suppl (2000), 273S–309S.
42. Pruim, R.J., Welch, R.P., Sanna, S., Teslovich, T.M., Chines, P.S., Gliedt, T.P., Boehnke, M., Abecasis, G.R., Willer, C.J., LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics 26 (2010), 2336–2337.
43. Romero Otero, J., Garcia Gomez, B., Campos Juanatey, F., Touijer, K.A., Prostate cancer biomarkers: an update. Urol. Oncol. 32 (2014), 252–260.
44. Schaid, D.J., McDonnell, S.K., Zarfas, K.E., Cunningham, J.M., Hebbring, S., Thibodeau, S.N., Eeles, R.A., Easton, D.F., Foulkes, W.D., Simard, J., et al. Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics. Hum. Genet. 120 (2006), 471–485.
45. Sen, S., Churchill, G.A., A statistical framework for quantitative trait mapping. Genetics 159 (2001), 371–387.
46. Shabalin, A.A., Matrix eQTL: ultra fast eQTL analysis via large matrix operations. Bioinformatics 28 (2012), 1353–1358.
47. Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2016. CA Cancer J. Clin. 66 (2016), 7–30.
48. Stephens, M., Smith, N.J., Donnelly, P., A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 68 (2001), 978–989.
49. Svenson, K.L., Gatti, D.M., Valdar, W., Welsh, C.E., Cheng, R., Chesler, E.J., Palmer, A.A., McMillan, L., Churchill, G.A., High-resolution genetic mapping using the Mouse Diversity outbred population. Genetics 190 (2012), 437–447.
50. Taylor, B.S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B.S., Arora, V.K., Kaushik, P., Cerami, E., Reva, B., et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18 (2010), 11–22.
51. Teerlink, C.C., Thibodeau, S.N., McDonnell, S.K., Schaid, D.J., Rinckleb, A., Maier, C., Vogel, W., Cancel-Tassin, G., Egrot, C., Cussenot, O., et al., International Consortium for Prostate Cancer Genetics. Association analysis of 9,560 prostate cancer cases from the International Consortium of Prostate Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease. Hum. Genet. 133 (2014), 347–356.
52. Thibodeau, S.N., French, A.J., McDonnell, S.K., Cheville, J., Middha, S., Tillmans, L., Riska, S., Baheti, S., Larson, M.C., Fogarty, Z., et al. Identification of candidate genes for prostate cancer-risk SNPs utilizing a normal prostate tissue eQTL data set. Nat. Commun., 6, 2015, 8653.
53. Vavouri, T., McEwen, G.K., Woolfe, A., Gilks, W.R., Elgar, G., Defining a genomic radius for long-range enhancer action: duplicated conserved non-coding elements hold the key. Trends Genet. 22 (2006), 5–10.
54. Wang, H.T., Yao, Y.H., Li, B.G., Tang, Y., Chang, J.W., Zhang, J., Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis. J. Clin. Oncol. 32 (2014), 3383–3390.
55. Williams, K.A., Lee, M., Hu, Y., Andreas, J., Patel, S.J., Zhang, S., Chines, P., Elkahloun, A., Chandrasekharappa, S., Gutkind, J.S., et al. A systems genetics approach identifies CXCL14, ITGAX, and LPCAT2 as novel aggressive prostate cancer susceptibility genes. PLoS Genet., 10, 2014, e1004809.
56. Wilt, T.J., Dahm, P., PSA screening for prostate cancer: why saying no is a high-value health care choice. J. Natl. Compr. Canc. Netw. 13 (2015), 1566–1574.
57. Yeager, M., Orr, N., Hayes, R.B., Jacobs, K.B., Kraft, P., Wacholder, S., Minichiello, M.J., Fearnhead, P., Yu, K., Chatterjee, N., et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat. Genet. 39 (2007), 645–649.